In conclusion, male patients currently receiving CTLA-4 inhibitor and PD-1/PD-L1 inhibitor combination therapy have the highest incidence of IH, followed by CTLA-4 inhibitor monotherapy, and there may be a dose-dependent relationship. This evidence concerns the gene CD274 and isolated hemihyperplasia.